Meridian Bioscience Inc. (VIVO)
(Delayed Data from NSDQ)
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.51 USD
-0.48 (-4.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 1.56% and 1.72%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Beats Q4 Earnings Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 6.90% and 6.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of 52.38% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ascend Wellness Holdings, Inc. (AAWH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -125% and 6.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -8% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Meridian Bioscience (VIVO) Meets Q3 Earnings Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 0% and 1.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 43.75% and 2.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Computer Programs and Systems (CPSI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Computer Programs and Systems (CPSI) and Meridian Bioscience (VIVO) have performed compared to their sector so far this year.
Why Earnings Season Could Be Great for Meridian Bioscience (VIVO)
by Zacks Equity Research
Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.